AdvaMed Accel® Webinar: NIH SBIR/STTR Funding Opportunities

DeChane Dorsey, Executive Director of AdvaMed Accel and a  leading voice for early-stage innovation, to explore why this year’s programming is especially critical for small companies and entrepreneurs.

WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on the collaboration between Revival Healthcare Capital and Olympus Corporation to co-found Swan EndoSurgical, Inc. to develop a robotics platform to provide earlier, safer, and more effective treatment of lesions or tumors in the gastrointestinal tract relative to current therapeutic options. 

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

EPAM recently published a case study highlighting the rise of composable commerce solutions to enable B2B processes in the healthcare industry. This piece focuses on the experience of diagnostics company, Cepheid – a part of Danaher Corporation.

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

Learn how the EY Clinical Trial Fast Lane solution helps jumpstart clinical trials in 45 to 60 working days through rapid performance of functional services, deep understanding of clinical trial operations, and more.

AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.